source
- Skyhawk Therapeutics reports symptom improvement for Huntington's disease in Phase 1/2 extension studySkyhawk Therapeutics announced that its RNA-splicing candidate SKY-0515 showed a measurable improvement in symptoms for patients with Huntington's disease during an extension of its Phase 1/2 trial…
- Experts urge more representative enrollment in clinical trialsA panel of regulators and industry leaders gathered to discuss how clinical trials can better reflect the diversity of patient populations. The discussion included officials from the U.S. Food and…